

## Supplemental Material

**Figure S1.** The 2b-block SSO promotes Mnk2a production and activates the p38-MAPK stress pathway in hepatocellular carcinoma and metastatic breast carcinoma cells.

**A.** RT-PCR analysis of mRNA isolated from either HuH7 hepatocellular carcinoma (left panel) or MDA-MB-231 metastatic breast carcinoma cells (right panel) transfected with 2.5 $\mu$ M of either SCR, 2a-block or 2b-block 2'-OMe oligos 72h post transfection. \* $p < 0.01$ ,  $n = 6$  for each group. **B.** Western blot analysis of protein lysates from either HuH7 hepatocellular carcinoma (left panel) or MDA-MB-231 metastatic breast carcinoma cells (right panel) transfected with 2.5 $\mu$ M of either SCR, 2a-block or 2b-block 2'-OMe oligos 72h post transfection. Membranes were probed with the indicated antibodies. **C,D.** qRT-PCR analysis of mRNA isolated from either HuH7 hepatocellular carcinoma (C) or MDA-MB-231 metastatic breast carcinoma cells (D) transfected with 2.5 $\mu$ M of either SCR, 2a-block or 2b-block 2'-OMe oligos 72h post transfection. \* $p < 0.05$  two-sided, \*\* $p < 0.01$  two-sided,  $n = 3$  for each group.

**Figure S2.** The 2b-block SSO switches *MKNK2* alternative splicing, activates the p38 $\alpha$ -MAPK stress pathway and inhibits the oncogenic properties of U251MG glioblastoma cells.




**A.** RT-PCR analysis of mRNA isolated from U251MG glioblastoma cells transfected with 1 $\mu$ M of the indicated 2'-MOE oligos 72h post transfection. **B.** Western blot analysis of protein lysates from U251MG glioblastoma cells transfected with 1 $\mu$ M of the indicated 2'-MOE oligos 72h post transfection. Membranes were probed with the indicated antibodies. **C.** qRT-PCR analysis of mRNA isolated from U251MG glioblastoma cells transfected with 1 $\mu$ M of the indicated 2'-MOE oligos 72h post transfection. \* $p < 0.01$  two-sided,  $n = 3$ . **D.** Colony formation in soft agar assay performed on U251MG glioblastoma cells transfected with 1 $\mu$ M of the indicated 2'-MOE oligos.  $n = 3$  wells for each group, in each well 10 fields were counted. **E.** Clonogenic assay performed on U251MG glioblastoma cells transfected with 1 $\mu$ M of the indicated 2'-MOE oligos and seeded at low density. The number of colonies in each treatment was normalized to number of colonies of non-treated cells.  $n = 3$  wells for each group.

**Figure S3.** SSO mediated switch in Mnk2 splicing affects survival of hepatocellular carcinoma and metastatic breast carcinoma cells.

**A.** Colony formation in soft agar assay performed on MDA-MB-231 cells transfected with 2.5 $\mu$ M of the indicated 2'-OMe oligos. \*\* $p < 0.01$  two-sided,  $n = 3$  wells for each group, in each well 10 fields were counted. **B, C.** Clonogenic assay performed on HuH7 (B) and MDA-MB-231 (C) cells transfected with 2.5 $\mu$ M of the indicated 2'-OMe oligos and seeded at a low density. The number of colonies in each treatment was normalized to number of colonies in cells treated with SCR oligo. \* $p < 0.05$  two-sided, \*\* $p < 0.01$  two-sided,  $n = 3$  wells for each group. **D.** Colony formation in soft agar assay performed on U87MG glioma cells transfected with the indicated 2'-MOE oligos. \*\* $p < 0.01$  two-sided,  $n = 2$  wells for each group, in each well 10 fields were counted. **E.** Clonogenic assay performed on U87MG glioma cells transfected with the indicated 2'-MOE oligos and seeded at a low density. The number of colonies in each treatment was normalized to number of colonies in cells treated with SCR oligo.

**Figure S4.** The 2b-block 2'-MOE SSO sensitizes U87MG and U251MG glioblastoma cells to TMZ, doxorubicin and CDDP in culture.

**A.** Trypan blue exclusion assay performed on U251MG cells transfected with 1 $\mu$ M of the indicated 2'-MOE oligos and treated with 8 $\mu$ g/ $\mu$ l doxorubicin (blue bars) or vehicle (black bars) for 48h. \* $p \leq 0.05$  two-sided,  $n = 3$  wells for each group. **B.** Trypan blue exclusion assay performed on U251MG cells transfected with 1 $\mu$ M of the indicated 2'-MOE oligos and treated with 100 $\mu$ M CDDP (blue bars) or vehicle (black bars) for 48h. \* $p \leq 0.05$  two-sided,  $n = 3$  wells for each group. **C.** Trypan blue exclusion assay performed on U251MG cells transfected with 1 $\mu$ M of the indicated 2'-MOE oligos and treated with 500 $\mu$ M TMZ (blue bars) or vehicle (black bars) for 72h. \* $p \leq 0.05$  two-sided, \*\* $p \leq 0.01$  two-sided,  $n = 3$  wells for each group.

**A****B****C****D**